65,437 trials
Parkinson Disease
Primary: Proportion of aDBS Subjects With "On" Time Without Troublesome Dyskinesia Exceeding the Threshold. — 78.9; 91 percentage of participant
Posttraumatic Stress Disorder · Tinnitus
Primary: Resting-State Functional MRI — 0.55; 0.35; 0.29; 0.59 Z-Score — p=0.01
Aphasia, Acquired
Primary: Change in Protocol Compliance — 67.35; 86.98 Percent response/n scheduled prompts — p=0.021
Asthma
Primary: Percentage Endorsement of Responses by Site HCPs for Each Categorical Item on the Post-study Survey Relating to Overall Ease of Implementing AIRQ Into Clinical Practice…
Coronary Arterial Disease (CAD) · Coronary Artery Bypass · LIMA
Primary: Reliability of Bidirectional Palpation Test (BPT) in Evaluating LIMA-LAD Graft Patency — 2; 2; 2; 2 Participants — p=<0.001
Spinal Fusion
Primary: Number of Participants With Successful Fusion Status at Month 12 Post-Procedure — 17; 16; 16 Participants
Covid19
Primary: Number of Bacterial Colony Forming Units (CFUs) — 47.2; 125.3; 70.7; 116.7 bacterial colony forming units (CFUs)
Asthma
Primary: Mean Number of Daily Doses of ProAir® Digihaler™ — 0.55 doses per day
Type2 Diabetes · Coronary Artery Disease
Primary: EAT Inflammation — 0.70; 1.4; 0.39; 0.25 ct (cycle threshold)
Respiratory Syncytial Virus (RSV)
Primary: Part 1: Concentrations of EDP-938 in Plasma — 1132.222; 1989.500; 1819.286; 1420.000 ng/mL
High Grade Glioma · Ependymoma
Primary: Safety of the Optune NovoTTF-200A System When Used Alone in Pediatric Patients With Recurrent High-grade Gliomas. — 0 Participants
Diffuse Large B-cell Lymphoma
Primary: 1 Year Progression Free Survival (PFS) — 58 Percentage of participants
Critical Limb Ischemia · Peripheral Arterial Disease
Primary: Primary Effectiveness Endpoint: Late Lumen Loss (LLL) at 9 Months — 0.892; 1.312 mm
Rotator Cuff Tendinitis · Syndrome Rotator Cuff · Tendinopathy
Primary: Change From Baseline in Constant-Murley Score (CMS) at 3 Months — 10.03 units on a scale — p=0.001
PreDiabetes · Overweight and Obesity · Type 2 Diabetes
Primary: Adult Participant Attendance in Program as Assessed by Total Number of Required Program Sessions Attended, Core — 17.6; 14.8; 13.5; 1.4 sessions